F60.2
Conditions
Interventions
Group 1: Intranasal oxytocin, total of 24 IU (administered in 6 doses of nasal spray, alternating between nostrils, 45 seconds between puffs)
Group 2: Intranasal placebo (total of 6 doses of nasal spr
Sponsors
Heidelberg University Hospital, Department of General Psychiatry
Eligibility
Sex/Gender
All
Age
18 Years to 30 Years
Inclusion criteria
Inclusion criteria: ASPD participants had to fulfil the DSM-IV, respectively DSM-5, criteria for ASPD (according to the International Personality Disorder Examination (IPDE))
Exclusion criteria
Exclusion criteria: Exclusion criteria for all participants were an intelligence quotient (IQ) lower than 80, insufficient German language skills, pregnancy, breast feeding, claustrophobia, any current medication (except oral contraceptives and levothyroxine), past cranio-cerebral injuries, and somatic, endocrine, or neurological diseases. Additional exclusion criteria for ASPD participants were autism spectrum disorder, lifetime diagnoses of schizophrenia or bipolar disorder, and current alcohol or drug dependence. Additional exclusion criteria for HC participants were any lifetime or current mental disorder or personality disorder and any psychological/psychiatric treatment assessed by the Structured Clinical Interview for DSM-IV (SCID-I) and antisocial behavior assessed by the International Personality Disorder Examination (IPDE).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amygdala activation in functional neuroimaging (fMRI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Correct classification of facial emotion expressions, response latencies | — |
Countries
Germany
Contacts
Public ContactHaang Jeung-Maarse
Universitätsklinikum für Psychiatrie und Psychotherapie
Outcome results
None listed